High Dose Nimodipine Treatment Adjunct - 1
Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine-Related Disorders
Intervention: Nimodipine (Drug)
Phase: Phase 2
Sponsored by: National Institute on Drug Abuse (NIDA)
Official(s) and/or principal investigator(s):
Steven Deutsch, M.D., Principal Investigator, Affiliation: Washington DC VA
The purpose of this study is to determine if nimodipine is more effective than placebo in
reducing stimulated craving for cocaine in cocaine dependent individuals denied access to
cocaine in inpatient unit.
Official title: High Dose Nimodipine Pharmacotherapy Adjunct
Study design: Primary Purpose: Treatment
Stimulated and non-stimulated craving
Stimulated and non-stimulated withdrawal
Minimum age: 22 Years.
Maximum age: 45 Years.
Please contact site for information.
Locations and Contacts
Washington DC VA, Washington, District of Columbia 20422, United States
Last updated: June 2, 2015